Anticoagulant Choice for Primary PCI in STEMI
A single patient already on the table for an emergent stent, and an anticoagulant decision the team is finalizing in the same minutes as the procedure itself. The disagreement is about how much the original bleeding-advantage data still apply now that the access route itself has changed.
P.R., a 60-year-old man, became a first-time grandfather three weeks ago, and still carries the ultrasound photo from before the birth folded in his wallet even now that there's a real baby to hold instead. He has treated hypertension and quit smoking eight years ago, not long after his own father died of a heart attack — a fact he brought up himself, unprompted, while the team was getting him ready for the catheterization lab. He woke this morning with sudden, crushing chest pain that hadn't let up by the time paramedics arrived, and his ECG showed ST-elevation across the anterior leads.
He's being activated for emergent primary PCI, access already established through the radial artery, and the anticoagulant chosen for the procedure itself is still being decided as the team preps him. Bivalirudin, a direct thrombin inhibitor, carries a well-documented bleeding advantage over unfractionated heparin in trials going back over a decade — but the earliest of those trials also showed a real increase in acute stent thrombosis within the first day when bivalirudin was used without a post-procedure infusion, a finding that later practice addressed by continuing bivalirudin at PCI-dose for a period after the stent goes in rather than stopping it the moment the procedure ends. More recent trials, run in an era when radial access was already standard rather than the exception, found the bleeding gap between bivalirudin and heparin narrower than the earliest data suggested — because radial access itself removes a large share of the bleeding risk that used to distinguish the two drugs regardless of which one was chosen.
Deciding in the minutes before the stent
I'd use bivalirudin, and I'd plan the post-procedure infusion at PCI dose from the start rather than deciding at the end of the case. The early stent-thrombosis signal from the original trials was real, but it was also specifically tied to stopping the drug the moment the procedure ended — continuing it afterward addresses that directly rather than requiring us to accept the tradeoff as fixed.
With radial access, which is what we already have here, the bleeding advantage bivalirudin showed in the original trials is substantially narrower than it used to be — a large share of that advantage came from femoral-access bleeding that radial access avoids regardless of which anticoagulant is chosen. Heparin monotherapy sidesteps the stent-thrombosis question entirely and is simpler to manage in a case that's already moving fast.
Simpler isn't nothing, especially in an emergent case, but it isn't a clinical advantage on its own — the actual ischemic and bleeding outcomes between the two strategies in radial-access-predominant trials came out close enough that "simpler" may be doing more of the deciding here than the data are.
The honest read is that radial access has narrowed the gap between these two options more than it has settled which one is better — recent trials with radial access as the norm show closer ischemic and bleeding outcomes between bivalirudin and heparin than the original studies did. Given that, I'd support either choice, but if bivalirudin is used, the post-PCI infusion decision needs to be made now, on the table, not left as a loose end at the end of the case — that's exactly the detail that produced the early stent-thrombosis problem the first time around.
Bivalirudin selected for this case with an explicit post-PCI infusion plan decided before the procedure started, not left for the end of the case; aspirin and ticagrelor loaded emergently. The choice between bivalirudin and heparin was not settled as a general rule — both cardiologists agreed radial access has narrowed the practical difference between them, and left the decision to be made case by case going forward rather than adopting either as a fixed default.